Item 8.01. Other Events.
On June 25, 2022, Arbutus Biopharma Corporation (the "Company") issued a press
release announcing the presentation of new clinical and pre-clinical data from
its proprietary compounds at the European Association for the Study of the Liver
(EASL) International Liver Congress™ (ILC) and providing an update on its AB-836
clinical development program.
On June 27, 2022, the Company held a conference call and webcast presentation to
discuss the new data. A copy of the presentation is filed herewith as Exhibit
99.2 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
99.1 Press release dated June 25, 2022
99.2 Presentation dated June 27, 2022
104 Cover page interactive data file (formatted as inline
XBRL).
© Edgar Online, source Glimpses